AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31220085 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 526
Study 31220085 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on heart rate terms, mid-upper arm circumference, malaria status, water source, family income, and sibling childcare status
Number of subjects: 526
Study 28345400 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐mix (3 g/dose)
Number of subjects: 10
Study 28345400 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g of dextrin/dose)
Number of subjects: 10
Study 25496283 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care family therapy (UC-FT)
Number of subjects: 205
Study 25496283 — intervention group
Group type: COMPARATOR
Intervention: Nonfamily treatment (UC-Other)
Number of subjects: 205
Study 23967066 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 6.0 g daily for 8 weeks
Number of subjects: 200
Study 23967066 — intervention group
Group type: COMPARATOR
Intervention: Placebo L-arginine for 8 weeks
Number of subjects: 200
Study 23967066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 IU 4-weekly for 8 weeks
Number of subjects: 200
Study 23967066 — intervention group
Group type: COMPARATOR
Intervention: Placebo vitamin D for 8 weeks
Number of subjects: 200
Study 23967066 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score (weight, FEV1, cough, sputum, haemoptysis)
Number of subjects: 200
Study 21890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 40
Study 21890081 — intervention group
Group type: COMPARATOR
Intervention: Low-fat Therapeutic Lifestyle Changes Diet (TLCD)
Number of subjects: 40
Study 21890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MD and TLCD
Number of subjects: 40
Study 19570145 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of entacapone with levodopa/DDCI
Number of subjects: 488
Study 19570145 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of entacapone with levodopa/DDCI (placebo)
Number of subjects: 488
Study 17949458 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min ischemic preconditioning (IPC)
Number of subjects: 101
Study 17949458 — intervention group
Group type: COMPARATOR
Intervention: No IPC
Number of subjects: 101
Study 15119641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue sealant (1 mL applied to the peritoneal cuff suture)
Number of subjects: 45
Study 15119641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue sealant)
Number of subjects: 45
Study 15119641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue sealant
Number of subjects: 45
Study 15119641 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue sealant and Control group
Number of subjects: 45
Study 11499330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg once daily for 1 or 2 weeks
Number of subjects: 14
Study 9160490 — intervention group
Group type: EXPERIMENTAL
Intervention: Older ad hoc methods
Number of subjects: 0
Study 9160490 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent statistical methods for multiple event data
Number of subjects: 0
Study 8425702 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg captopril
Number of subjects: 0
Study 3118827 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN supplemented with ornithine‐alpha‐ketoglutarate (0.35 g/kg bw/day)
Number of subjects: 15
Study 3118827 — intervention group
Group type: COMPARATOR
Intervention: TPN only (Control)
Number of subjects: 15
Study 31747326 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (440 μM) administered at first onset of ARIE and then weekly after final radiotherapy
Number of subjects: 0
Study 31747326 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (440 μM) administered for ARIE
Number of subjects: 0
Study 30112772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg as first-line treatment
Number of subjects: 0
Study 30112772 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 4 mg as first-line treatment
Number of subjects: 0
Study 26316552 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy task training (GT)
Number of subjects: 73
Study 26316552 — intervention group
Group type: COMPARATOR
Intervention: Individual task training (IT)
Number of subjects: 73
Study 25577723 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus ezetimibe (10 mg) daily
Number of subjects: 0
Study 25577723 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 0
Study 24314222 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-endostatin (Endostar) combined with docetaxel
Number of subjects: 68
Study 24314222 — intervention group
Group type: COMPARATOR
Intervention: Single docetaxel
Number of subjects: 68
Study 20575193 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous calcium phosphate-containing composite resin (ACP-containing)
Number of subjects: 40
Study 20575193 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite resin (Control)
Number of subjects: 40
Study 18394501 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group TRP(8)
Number of subjects: 66
Study 18394501 — intervention group
Group type: COMPARATOR
Intervention: Sham group TRP(8)
Number of subjects: 66
Study 18394501 — intervention group
Group type: COMPARATOR
Intervention: Control group TRP(8)
Number of subjects: 66
Study 18394501 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group TRP(30)
Number of subjects: 66
Study 18394501 — intervention group
Group type: COMPARATOR
Intervention: Sham group TRP(30)
Number of subjects: 66
Study 18394501 — intervention group
Group type: COMPARATOR
Intervention: Control group TRP(30)
Number of subjects: 66
Study 17109664 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25-1 mg daily
Number of subjects: 243
Study 17109664 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal conventional asthma therapy (NSCAT)
Number of subjects: 243
Study 12891539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tacrolimus 0.2 mg. kg(‐1). day(‐1)
Number of subjects: 48
Study 12891539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10492065 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Prednisone, and L-asparaginase (VPL)
Number of subjects: 0
Study 10492065 — intervention group
Group type: COMPARATOR
Intervention: VPL plus anthracyclines
Number of subjects: 0
Study 10492065 — intervention group
Group type: EXPERIMENTAL
Intervention: VPL with an anti-CD19 immunotoxin
Number of subjects: 0
Study 10492065 — intervention group
Group type: COMPARATOR
Intervention: Anthracyclines
Number of subjects: 0
Study 8731073 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural light treatment (1‐h morning walk outdoors)
Number of subjects: 0
Study 8731073 — intervention group
Group type: COMPARATOR
Intervention: Low‐dose artificial light (0.5 h@2800 lux)
Number of subjects: 0
Study 1836687 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 chemotherapeutic regimens at 3-monthly intervals
Number of subjects: 0
Study 6125287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 15
Study 6125287 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15
Study 6125287 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 6125287 — intervention group
Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 15
Study 2870548 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg per day for two months
Number of subjects: 128
Study 2870548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 28646480 — intervention group
Group type: EXPERIMENTAL
Intervention: Masculine play behavior
Number of subjects: 412
Study 28646480 — intervention group
Group type: COMPARATOR
Intervention: Control play behavior
Number of subjects: 412
Study 28646480 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine play behavior
Number of subjects: 412
Study 26944263 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Programme for the Last Days of Life
Number of subjects: 57
Study 26944263 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Guide for the Last Days of Life
Number of subjects: 57
Study 24592170 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietetic intervention
Number of subjects: 101
Study 22316141 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-weekly group-based skills training for adolescents followed by 6-weekly targeted newsletters for caregivers (Group 1)
Number of subjects: 0
Study 22316141 — intervention group
Group type: COMPARATOR
Intervention: Group-based skills training for adolescents only (Group 2)
Number of subjects: 0
Study 22316141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 0
Study 20650921 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 30
Study 20650921 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 30
Study 19119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Rhino Stammberger sinus dressing (RR)
Number of subjects: 24
Study 15931068 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% cinnamaldehyde
Number of subjects: 10
Study 15931068 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% menthol
Number of subjects: 10
Study 12716275 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (N = 851)
Number of subjects: 2046
Study 12716275 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs) (N = 749)
Number of subjects: 2046
Study 12716275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 446)
Number of subjects: 2046
Study 10348423 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (2 filter cigarettes over 10 minutes)
Number of subjects: 10
Study 10348423 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 10
Study 10348423 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 10
Study 7669466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 200
Study 7669466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 200
Study 7669466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium
Number of subjects: 200
Study 7669466 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 200
Study 7669466 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium combined with Vecuronium, Pipecuronium, or Pancuronium
Number of subjects: 200
Study 1955546 — intervention group
Group type: COMPARATOR
Intervention: Follicle aspiration only (Group 1)
Number of subjects: 0
Study 1955546 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle aspiration and flushing with 10 ml of flushing medium (Group 2)
Number of subjects: 0
Study 7304485 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (9.0 g/day)
Number of subjects: 24
Study 7304485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose in 600 mg capsules)
Number of subjects: 24
Study 31830211 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide, 160 mg once daily
Number of subjects: 1672
Study 30537138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified BP group (INTENS, target 24-hour MAP <50th percentile, n=12)
Number of subjects: 23
Study 30537138 — intervention group
Group type: COMPARATOR
Intervention: Standard BP group (STAND, target 24-hour MAP 50-95th percentile, n=11)
Number of subjects: 23
Study 30537138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified BP group (INTENS)
Number of subjects: 23
Study 30537138 — intervention group
Group type: COMPARATOR
Intervention: Standard BP group (STAND)
Number of subjects: 23
Study 28605263 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity activity breaks (20 two-minute breaks)
Number of subjects: 33
Study 28605263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity activity breaks (20 two-minute breaks)
Number of subjects: 33
Study 28605263 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity activity breaks (20 two-minute breaks)
Number of subjects: 33
Study 28605263 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting (20 two-minute sedentary computer game breaks)
Number of subjects: 33
Study 28605263 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PAEE
Number of subjects: 33
Study 26578734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance
Number of subjects: 1228
Study 26578734 — intervention group
Group type: COMPARATOR
Intervention: Minimal surveillance
Number of subjects: 1228
Study 26578734 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1228
Study 25208030 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel guidewire (270-cm, hyperflexible, hydrophilic tip with stiff shaft)
Number of subjects: 197
Study 25208030 — intervention group
Group type: COMPARATOR
Intervention: Standard group (260-cm long, angled-tip hydrophilic wire with nitinol wire as needed)
Number of subjects: 197
Study 25208030 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel guidewire
Number of subjects: 197
Study 25208030 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 197
Study 23021480 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-delivered Early Start Denver model (P-ESDM) intervention (1-hour/week for 12 weeks)
Number of subjects: 98
Study 23021480 — intervention group
Group type: COMPARATOR
Intervention: Community treatment as usual
Number of subjects: 98
Study 23021480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P-ESDM and community treatment)
Number of subjects: 98
Study 20193938 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review evaluation system
Number of subjects: 46
Study 17265052 — intervention group
Group type: EXPERIMENTAL
Intervention: Second MRI after preoperative radiotherapy
Number of subjects: 25
Study 15877041 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided learning (CAL)
Number of subjects: 0
Study 15877041 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 0
Study 15877041 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL programs
Number of subjects: 0
Study 11564356 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepharmacy counseling
Number of subjects: 36
Study 11564356 — intervention group
Group type: COMPARATOR
Intervention: Control group (written instructions)
Number of subjects: 36
Study 9780534 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 0
Study 9780534 — intervention group
Group type: COMPARATOR
Intervention: Bassini repair
Number of subjects: 0
Study 8163050 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylin infusion for 6 hours during postabsorptive and euglycaemic hyperinsulinaemic clamp phases.
Number of subjects: 7
Study 8163050 — intervention group
Group type: COMPARATOR
Intervention: Control infusion (placebo) for 6 hours during postabsorptive and euglycaemic hyperinsulinaemic clamp phases.
Number of subjects: 7
Study 3139279 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylstilbestrol (DES) or bilateral orchiectomy
Number of subjects: 265
Study 3139279 — intervention group
Group type: EXPERIMENTAL
Intervention: leutinizing hormone‐releasing hormone (LHRH) analog buserelin
Number of subjects: 265
Study 3139279 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate plus DES or orchiectomy
Number of subjects: 265
Study 30507710 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH followed by rivaroxaban
Number of subjects: 118
Study 30507710 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 118
Study 28097324 — intervention group
Group type: EXPERIMENTAL
Intervention: NRG-GBM-RPA model incorporating MGMT protein, c-Met protein, and clinical variables
Number of subjects: 452
Study 28097324 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT protein expression
Number of subjects: 452
Study 28097324 — intervention group
Group type: COMPARATOR
Intervention: MGMT promoter methylation
Number of subjects: 452
Study 28097324 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-marker analysis of protein biomarkers (MGMT, survivin, c-Met, pmTOR, Ki-67)
Number of subjects: 452
Study 25446068 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable position
Number of subjects: 18
Study 25446068 — intervention group
Group type: COMPARATOR
Intervention: Unfavorable position
Number of subjects: 18
Study 23160037 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium acetate/silica toothpaste
Number of subjects: 80
Study 23160037 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine/calcium carbonate paste
Number of subjects: 80
Study 21098692 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release hydromorphone 16 mg in the fasted state
Number of subjects: 30
Study 21098692 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release hydromorphone 16 mg after a high-fat breakfast
Number of subjects: 30
Study 21098692 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release hydromorphone 16 mg daily dose (4 mg qid) in the fasted state
Number of subjects: 30
Study 19408811 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse (150 mmol/L)
Number of subjects: 10
Study 19408811 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice (1030 ppm)
Number of subjects: 10
Study 17696669 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE screening tool
Number of subjects: 5972
Study 15768834 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate
Number of subjects: 11
Study 15768834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11403725 — intervention group
Group type: EXPERIMENTAL
Intervention: New point-of-care test for smoking
Number of subjects: 187
Study 9355212 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of recommended bed rest
Number of subjects: 203
Study 9355212 — intervention group
Group type: COMPARATOR
Intervention: 7 days of recommended bed rest
Number of subjects: 203
Study 8453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 80
Study 8453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80
Study 8453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine and Amitriptyline combined
Number of subjects: 80
Study 8453432 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 3513009 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 36
Study 3513009 — intervention group
Group type: COMPARATOR
Intervention: Unchanged conventional treatment
Number of subjects: 36
Study 31334768 — intervention group
Group type: EXPERIMENTAL
Intervention: Eighth edition AJCC/UICC staging system with integrated plasma EBV DNA
Number of subjects: 205
Study 31334768 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of pretreatment EBV values (<2300 vs ≥2300 copies/ml)
Number of subjects: 205
Study 31334768 — intervention group
Group type: COMPARATOR
Intervention: Seventh edition AJCC/UICC staging system
Number of subjects: 205
Study 29882276 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO; 40,000 IU)
Number of subjects: 44
Study 29882276 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%)
Number of subjects: 44
Study 25758941 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation during hospitalization and for up to four weeks after discharge
Number of subjects: 71
Study 25758941 — intervention group
Group type: COMPARATOR
Intervention: Standard care treatment and rehabilitation following usual guidelines for the treatment of stroke patients
Number of subjects: 71
Study 24392772 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation before resistance training (0.1g*kg(‐1) creatine before + 0.1g*kg(‐1) placebo after RT)
Number of subjects: 22
Study 24392772 — intervention group
Group type: COMPARATOR
Intervention: Placebo before resistance training + creatine after resistance training
Number of subjects: 22
Study 23390778 — intervention group
Group type: EXPERIMENTAL
Intervention: Original clopidogrel 600 mg
Number of subjects: 49
Study 23390778 — intervention group
Group type: COMPARATOR
Intervention: Generic clopidogrel 600 mg
Number of subjects: 49
Study 20039319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in IGFBP1 (rs35539615)
Number of subjects: 819
Study 20039319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in IGFBP3 (rs2453839)
Number of subjects: 819
Study 20039319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in IGF1 (rs35767)
Number of subjects: 819
Study 20039319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity stratification for IGFBP3 SNPs
Number of subjects: 819
Study 18284648 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 4 mg/day
Number of subjects: 0
Study 18284648 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 1 mg/day
Number of subjects: 0
Study 18284648 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg/day
Number of subjects: 0
Study 18284648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18284648 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 4 mg/day (women)
Number of subjects: 0
Study 15625258 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus nerve stimulator guided pudendal nerve block
Number of subjects: 90
Study 15625258 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone or in combination with placebo blocks
Number of subjects: 90
Study 12895220 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy with tetracycline
Number of subjects: 100
Study 12895220 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy with metronidazole
Number of subjects: 100
Study 12895220 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy with metronidazole (with metronidazole resistance)
Number of subjects: 100
Study 12895220 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy with metronidazole (without metronidazole resistance)
Number of subjects: 100